Incannex Healthcare opened lower at $1.96, compared with its previous close of $1.98. In the last trading session, the stock traded between $1.96 and $2.06. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Incannex Healthcare is now worth
$ 0.46
Resulting in a loss of
$ 99.54 (99.54%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.07 (+3.29%)
Day High
$2.06
Day Low
$1.96
Day Open
$1.96
Prev Close
$1.98
Volume
98,371
1W Return
-18.79%
1M Return
-30.02%
3M Return
-36.25%
6M Return
-54.97%
1Y Return
-81.11%
Fundamentals
Market Cap ($ Mn)
26
PE Ratio
-
PB Ratio
0.66
PEG Ratio
-
ROE
-592.45%
ROCE
-509.20%
EPS (TTM)
$-0.18
Investment Returns
1 Week
-18.79%
1 Month
-30.02%
3 Months
-36.25%
6 Months
-54.97%
9 Months
-75.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
25Aug
Incannex doses first patient in IHL-42X Phase 2 OSA study
Incannex doses first patient in DReAMzz Phase 2 study for IHL-42X. Prior RePOSA data showed up to 83% reduction in apnea-hypopnea index. Program holds FDA Fast Track designation for obstructive sleep apnea. All 14 US clinical sites have IRB approval for the new study.
2mo ago
25Jun
Incannex secures US patent for OSA treatment IHL-42X
Incannex Healthcare secured a U.S. patent for IHL-42X, a novel oral combination therapy for Obstructive Sleep Apnea, valid until 9 July 2040. The company aims to extend the patent term post-FDA approval to bolster long-term exclusivity. This milestone strengthens Incannex's intellectual property portfolio for its lead clinical program.
4mo ago
10Jun
Incannex Healthcare receives A$6.04M under R&D tax incentive program
Incannex Healthcare secured A$6,039,162.43 via the Australian Government's Research and Development Tax Incentive Program, with another A$5.1 million expected in 2026. The over A$11.1 million in non-dilutive capital will support clinical development and capital allocation.
5mo ago
9Jun
Alliance Global initiates Incannex coverage with Buy rating
Alliance Global Partners has initiated equity research coverage on Incannex Healthcare with a Buy rating and a price target of US$18.00 per share. Analyst James Molloy authored the report, which assesses the company's clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder.
